NO20020758L - N<o>6</o> heterocykliske substituerte adenosinderivater - Google Patents

N<o>6</o> heterocykliske substituerte adenosinderivater

Info

Publication number: NO20020758L
Authority: NO; Norway
Prior art keywords: heterocyclic substituted; adenosine derivatives; substituted adenosine; sub; substituted
Prior art date: 1996-08-27

Application number

NO20020758A

Other languages

English (en)

Other versions

NO20020758D0 (no

NO322459B1 (no

Inventor

Robert T Lum

Jurg R Pfister

Steven R Schow

Michael M Wick

Marek G Nelson

George F Schreiner

Original Assignee

Cv Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

2002-02-15

Publication date

1999-02-19

1999-02-19 Publication of NO20020758L publication Critical patent/NO20020758L/no

2002-02-15 Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc

2002-02-15 Priority to NO20020758A priority Critical patent/NO322459B1/no

2002-02-15 Publication of NO20020758D0 publication Critical patent/NO20020758D0/no

2006-10-09 Publication of NO322459B1 publication Critical patent/NO322459B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20020758A 1996-08-27 2002-02-15 N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament. NO322459B1 (no)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NO20020758A NO322459B1 (no)	1996-08-27	2002-02-15	N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US08702234 US5789416B1 (en)	1996-08-27	1996-08-27	N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en)	1996-08-27	1997-08-20	N6 heterocyclic substituted adenosine derivatives
NO19990787A NO312679B1 (no)	1996-08-27	1999-02-19	N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020758A NO322459B1 (no)	1996-08-27	2002-02-15	N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Publications (3)

Publication Number	Publication Date
NO20020758L true NO20020758L (no)	1999-02-19
NO20020758D0 NO20020758D0 (no)	2002-02-15
NO322459B1 NO322459B1 (no)	2006-10-09

Family

ID=24820367

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO19990787A NO312679B1 (no)	1996-08-27	1999-02-19	N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020759A NO20020759D0 (no)	1996-08-27	2002-02-15	N<o>6</o> heterocykliske substituerte adenosinderivater
NO20020758A NO322459B1 (no)	1996-08-27	2002-02-15	N6 heterocykliske substituerte adenosinderivater, farmasoytiske sammensetninger omfattende samme, og anvendelse av samme for fremstilling av medikament.

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
NO19990787A NO312679B1 (no)	1996-08-27	1999-02-19	N6 heterocykliske substituerte adenosinderivater, farmasöytisk sammensetning inneholdende samme, og anvendelse avsamme for fremstilling av preparat
NO20020759A NO20020759D0 (no)	1996-08-27	2002-02-15	N<o>6</o> heterocykliske substituerte adenosinderivater

Country Status (24)

Country	Link
US (1)	US5789416B1 (no)
EP (3)	EP0920438B1 (no)
JP (1)	JP3157842B2 (no)
KR (1)	KR100331775B1 (no)
CN (1)	CN100363377C (no)
AT (2)	ATE202361T1 (no)
AU (1)	AU726597B2 (no)
BR (1)	BR9711444A (no)
CA (1)	CA2264155C (no)
CZ (1)	CZ296855B6 (no)
DE (2)	DE69719816T2 (no)
DK (2)	DK0992510T3 (no)
ES (2)	ES2157593T3 (no)
GE (1)	GEP20012419B (no)
GR (1)	GR3036332T3 (no)
HU (1)	HU226057B1 (no)
IL (2)	IL128652A0 (no)
NO (3)	NO312679B1 (no)
NZ (3)	NZ334095A (no)
PL (1)	PL187635B1 (no)
PT (1)	PT920438E (no)
TR (2)	TR199900377T2 (no)
UA (1)	UA62936C2 (no)
WO (1)	WO1998008855A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6790839B2 (en)	1999-01-07	2004-09-14	Can-Fite Biopharma Ltd.	Pharmaceutical administration of adenosine agonists
IL127947A0 (en)	1999-01-07	1999-11-30	Can Fite Technologies Ltd	Pharmaceutical use of adenosine agonists
US6576619B2 (en) *	1999-05-24	2003-06-10	Cv Therapeutics, Inc.	Orally active A1 adenosine receptor agonists
JP2003501431A (ja) *	1999-05-25	2003-01-14	ザペンステートリサーチファウンデイション	Ｄｎａメチル基転移酵素阻害剤
EP1420021A1 (en) *	1999-05-25	2004-05-19	The Penn State Research Foundation	DNA Methyltransferase inhibitors
US6180615B1 (en) *	1999-06-22	2001-01-30	Cv Therapeutics, Inc.	Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en)	1999-11-23	2004-08-31	Aderis Pharmaceuticals, Inc.	Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6258793B1 (en)	1999-12-03	2001-07-10	Cv Therapeutics, Inc.	N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) *	1999-12-03	2003-08-12	Cv Therapeutics, Inc.	Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
WO2001040799A2 (en) *	1999-12-03	2001-06-07	Cv Therapeutics, Inc.	Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6294522B1 (en) *	1999-12-03	2001-09-25	Cv Therapeutics, Inc.	N6 heterocyclic 8-modified adenosine derivatives
ES2215146T3 (es) *	2000-09-08	2004-10-01	Cv Therapeutics, Inc.	Utilizacion de ribosidos purina como antiarritmicos.
GB0100623D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds IV
EP1241176A1 (en) *	2001-03-16	2002-09-18	Pfizer Products Inc.	Purine derivatives for the treatment of ischemia
US20050227933A1 (en) *	2001-11-29	2005-10-13	Benkovic Stephen J	Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
US7405304B2 (en) *	2002-01-10	2008-07-29	The Penn State Research Foundation	Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids
KR20040084929A (ko)	2002-02-19	2004-10-06	씨브이 쎄러퓨틱스, 인코포레이티드	부분적이거나 완전한 ａ1 아데노신 수용체의 작용제
AU2003235466C1 (en) *	2002-04-18	2008-03-20	Gilead Palo Alto, Inc.	Method for treating arrhythmias
JP2006502974A (ja)	2002-05-17	2006-01-26	ニューロジェンコーポレイション	置換環縮合イミダゾール誘導体：ｇａｂａａ受容体リガンド
US7163928B2 (en) *	2003-02-03	2007-01-16	Cv Therapeutics, Inc.	Partial and full agonists of A1 adenosine receptors
US7834014B2 (en)	2003-04-09	2010-11-16	Biogen Idec Ma Inc.	A2a adenosine receptor antagonists
WO2004092177A1 (en)	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolopyrazines and methods of making and using the same
WO2004092170A2 (en)	2003-04-09	2004-10-28	Biogen Idec Ma Inc.	Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
CA2523746A1 (en) *	2003-04-24	2004-11-25	Aderis Pharmaceuticals, Inc.	Method of treating atrial fibrillation or atrial flutter
WO2005025545A2 (en) *	2003-09-17	2005-03-24	Aderis Pharmaceuticals, Inc.	Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en)	2003-11-24	2009-08-11	Pfizer Inc	Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) *	2004-04-21	2005-04-19	Eastman Chemical Company	Preparation of tetrahydro-3-furoic acid
EP2221307A1 (en) *	2004-05-26	2010-08-25	Inotek Pharmaceuticals Corporation	Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
NZ554506A (en) *	2004-09-20	2011-01-28	Inotek Pharmaceuticals Corp	Purine derivatives and methods of use thereof
CN100451010C (zh) *	2004-12-21	2009-01-14	厦门大学	一种合成(r)-3-氨基四氢呋喃的方法
WO2006125190A1 (en) *	2005-05-19	2006-11-23	Cv Therapeutics, Inc.	A1 adenosine receptor agonists
RU2008122978A (ru)	2005-11-09	2009-12-20	Комбинаторкс, Инкорпорейтед (Us)	Способы, композиции и наборы для лечения медицинских состояний
CN100344768C (zh) *	2005-11-24	2007-10-24	东华大学	一种3－(s)－氨基四氢呋喃的酶法合成方法
US7732424B2 (en) *	2005-11-30	2010-06-08	Inotek Pharmaceuticals Corporation	Purine derivatives and methods of use thereof
CN102016036B (zh)	2008-02-11	2015-04-08	阿克赛医药公司	经修饰的RNAi多核苷酸及其用途
WO2010008582A2 (en)	2008-07-18	2010-01-21	Rxi Pharmaceuticals Corporation	Phagocytic cell drug delivery system
CA2743981C (en)	2008-09-22	2019-01-29	Rxi Pharmaceuticals Corporation	Reduced size self-delivering rnai compounds
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
US9493774B2 (en)	2009-01-05	2016-11-15	Rxi Pharmaceuticals Corporation	Inhibition of PCSK9 through RNAi
US9745574B2 (en)	2009-02-04	2017-08-29	Rxi Pharmaceuticals Corporation	RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
SI2523669T1 (sl)	2010-01-11	2017-05-31	Inotek Pharmaceuticals Corporation	Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
US9080171B2 (en)	2010-03-24	2015-07-14	RXi Parmaceuticals Corporation	Reduced size self-delivering RNAi compounds
KR20180044433A (ko)	2010-03-24	2018-05-02	알엑스아이 파마슈티칼스 코포레이션	진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
WO2011119871A1 (en)	2010-03-24	2011-09-29	Rxi Phrmaceuticals Corporation	Rna interference in ocular indications
SG184221A1 (en)	2010-03-26	2012-10-30	Inotek Pharmaceuticals Corp	Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
DE102011005232A1 (de)	2011-03-08	2012-09-13	AristoCon GmbH & Co. KG	Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
SG11201403979TA (en)	2012-01-26	2014-08-28	Inotek Pharmaceuticals Corp	Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
SG11201506882YA (en)	2013-03-15	2015-09-29	Inotek Pharmaceuticals Corp	Ophthalmic formulations
US10934550B2 (en)	2013-12-02	2021-03-02	Phio Pharmaceuticals Corp.	Immunotherapy of cancer
KR20160110370A (ko)	2013-12-04	2016-09-21	알엑스아이 파마슈티칼스 코포레이션	화학적으로 변형된 올리고뉴클레오티드를 사용한 상처 치유의 치료 방법
EP3137119B1 (en)	2014-04-28	2020-07-01	Phio Pharmaceuticals Corp.	Methods for treating cancer using a nucleic acid targeting mdm2
WO2015168605A1 (en)	2014-05-01	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
CN107073294A (zh)	2014-09-05	2017-08-18	阿克赛医药公司	使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
KR20180026739A (ko)	2015-07-06	2018-03-13	알엑스아이 파마슈티칼스 코포레이션	슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
CN109563509B (zh)	2015-10-19	2022-08-09	菲奥医药公司	靶向长非编码rna的减小尺寸的自递送核酸化合物
CN105218490B (zh) *	2015-11-10	2017-05-03	山东川成医药股份有限公司	一种（r）‑3‑氨基四氢呋喃的制备方法
WO2018195355A1 (en)	2017-04-19	2018-10-25	Rxi Pharmaceuticals Corporation	Topical delivery of nucleic acid compounds
US20230002766A1 (en)	2019-11-08	2023-01-05	Phio Pharmaceuticals Corp.	Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2021138537A1 (en)	2019-12-31	2021-07-08	Phio Pharmaceuticals Corp.	Chemically modified oligonucleotides with improved systemic delivery
WO2023015264A1 (en)	2021-08-04	2023-02-09	Phio Pharmaceuticals Corp.	Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
KR20240041973A (ko)	2021-08-04	2024-04-01	피오 파마슈티칼스 코프.	화학적으로 변형된 올리고뉴클레오티드

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2460929A1 (de) *	1974-12-21	1976-06-24	Boehringer Sohn Ingelheim	Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) *	1980-10-14	1982-12-21	University Of Virginia Alumni Patents Foundation	Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) *	1981-04-15	1982-10-22	Fujisawa Pharmaceut Co Ltd	Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) *	1981-09-26	1983-04-07	Hoechst Ag, 6230 Frankfurt	"arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
AU577743B2 (en) *	1984-10-26	1988-09-29	Warner-Lambert Company	N6-benzopyrano and benzothiopyrano adenosines
WO1988003148A2 (en) *	1986-10-31	1988-05-05	Warner-Lambert Company	Heteroaromatic derivatives of adenoside
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) *	1987-04-24	1996-10-15	Discovery Therapeutics, Inc.	N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) *	1988-06-30	1990-12-25	The University Of Virginia	Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) *	1988-08-25	1990-02-25	Prendergast Patrick T	Viral treatment system
DE3843117A1 (de) *	1988-12-22	1990-06-28	Boehringer Ingelheim Kg	Neue xanthinderivate mit adenosin-antagonistischer wirkung
AU626983B2 (en) *	1989-01-31	1992-08-13	Whitby Research, Inc.	N6-substituted 9-methyladenines
US5155098A (en) *	1989-06-09	1992-10-13	Hoechst-Roussel Pharmaceuticals Inc.	N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5017578A (en) *	1989-06-09	1991-05-21	Hoechst-Roussel Pharmaceuticals Inc.	N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) *	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
DE4019892A1 (de) *	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
US5432164A (en) *	1991-10-24	1995-07-11	Novo Nordisk A/S	C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) *	1992-02-21	2005-11-24	Glüsenkamp, Karl-Heinz, Dr.	Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) *	1992-09-22	1994-02-22	Cell Therapeutics, Inc.	Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) *	1993-01-26	1994-08-04	Kyowa Hakko Kogyo Co., Ltd.	Medicament contre l'elimination irreguliere des matieres fecales
US5736528A (en) *	1993-10-28	1998-04-07	University Of Florida Research Foundation, Inc.	N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) *	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
EP0704215A3 (en) *	1994-06-02	1998-04-01	Takeda Chemical Industries, Ltd.	Inhibitor of vascular permeability enhancer

1996
- 1996-08-27 US US08702234 patent/US5789416B1/en not_active Expired - Lifetime
1997
- 1997-08-20 IL IL12865297A patent/IL128652A0/xx active IP Right Grant
- 1997-08-20 EP EP97938502A patent/EP0920438B1/en not_active Expired - Lifetime
- 1997-08-20 KR KR1019997001563A patent/KR100331775B1/ko not_active Expired - Fee Related
- 1997-08-20 AU AU40809/97A patent/AU726597B2/en not_active Ceased
- 1997-08-20 TR TR1999/00377T patent/TR199900377T2/xx unknown
- 1997-08-20 AT AT97938502T patent/ATE202361T1/de active
- 1997-08-20 JP JP51173698A patent/JP3157842B2/ja not_active Expired - Fee Related
- 1997-08-20 DK DK99119389T patent/DK0992510T3/da active
- 1997-08-20 ES ES97938502T patent/ES2157593T3/es not_active Expired - Lifetime
- 1997-08-20 EP EP99119389A patent/EP0992510B1/en not_active Expired - Lifetime
- 1997-08-20 UA UA99021148A patent/UA62936C2/uk unknown
- 1997-08-20 DE DE69719816T patent/DE69719816T2/de not_active Expired - Lifetime
- 1997-08-20 CN CNB971991790A patent/CN100363377C/zh not_active Expired - Fee Related
- 1997-08-20 NZ NZ334095A patent/NZ334095A/xx not_active IP Right Cessation
- 1997-08-20 EP EP00123879A patent/EP1081155A3/en not_active Withdrawn
- 1997-08-20 GE GEAP19974728A patent/GEP20012419B/en unknown
- 1997-08-20 CZ CZ0061499A patent/CZ296855B6/cs not_active IP Right Cessation
- 1997-08-20 DK DK97938502T patent/DK0920438T3/da active
- 1997-08-20 CA CA002264155A patent/CA2264155C/en not_active Expired - Fee Related
- 1997-08-20 AT AT99119389T patent/ATE234323T1/de active
- 1997-08-20 HU HU0001640A patent/HU226057B1/hu not_active IP Right Cessation
- 1997-08-20 WO PCT/US1997/014724 patent/WO1998008855A2/en not_active Ceased
- 1997-08-20 PT PT97938502T patent/PT920438E/pt unknown
- 1997-08-20 DE DE69705312T patent/DE69705312T2/de not_active Expired - Lifetime
- 1997-08-20 PL PL97331853A patent/PL187635B1/pl not_active IP Right Cessation
- 1997-08-20 TR TR2002/02287T patent/TR200202287T2/xx unknown
- 1997-08-20 ES ES99119389T patent/ES2189330T3/es not_active Expired - Lifetime
- 1997-08-20 NZ NZ505428A patent/NZ505428A/en unknown
- 1997-08-20 BR BR9711444-8A patent/BR9711444A/pt active Search and Examination
1999
- 1999-02-19 NO NO19990787A patent/NO312679B1/no not_active IP Right Cessation
- 1999-02-22 IL IL128652A patent/IL128652A/en not_active IP Right Cessation
2001
- 2001-06-08 NZ NZ512242A patent/NZ512242A/xx not_active IP Right Cessation
- 2001-08-06 GR GR20010401184T patent/GR3036332T3/el unknown
2002
- 2002-02-15 NO NO20020759A patent/NO20020759D0/no not_active Application Discontinuation
- 2002-02-15 NO NO20020758A patent/NO322459B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69705312T2 (de)	2001-10-11
ES2157593T3 (es)	2001-08-16
DE69719816T2 (de)	2003-12-18
IL128652A (en)	2008-06-05
ES2189330T3 (es)	2003-07-01
CA2264155A1 (en)	1998-03-05
NZ334095A (en)	2000-10-27
TR200202287T2 (tr)	2003-01-21
KR100331775B1 (ko)	2002-04-09
WO1998008855A3 (en)	1998-09-03
PL187635B1 (pl)	2004-08-31
PT920438E (pt)	2001-10-30
NO990787L (no)	1999-02-19
NO20020758D0 (no)	2002-02-15
EP1081155A3 (en)	2003-05-02
DK0992510T3 (da)	2003-07-07
CZ296855B6 (cs)	2006-07-12
GEP20012419B (en)	2001-04-25
NO20020759L (no)	1999-02-19
WO1998008855A2 (en)	1998-03-05
ATE202361T1 (de)	2001-07-15
CZ61499A3 (cs)	1999-10-13
CA2264155C (en)	2003-11-18
AU726597B2 (en)	2000-11-16
HU226057B1 (en)	2008-04-28
EP0992510A1 (en)	2000-04-12
US5789416A (en)	1998-08-04
CN1234803A (zh)	1999-11-10
KR20000035867A (ko)	2000-06-26
UA62936C2 (en)	2004-01-15
NO990787D0 (no)	1999-02-19
HK1020967A1 (en)	2000-05-26
GR3036332T3 (en)	2001-11-30
EP0920438B1 (en)	2001-06-20
DE69705312D1 (de)	2001-07-26
HUP0001640A2 (hu)	2001-05-28
NO20020759D0 (no)	2002-02-15
ATE234323T1 (de)	2003-03-15
BR9711444A (pt)	2000-01-18
NZ512242A (en)	2004-01-30
CN100363377C (zh)	2008-01-23
NO322459B1 (no)	2006-10-09
TR199900377T2 (xx)	1999-05-21
NZ505428A (en)	2005-03-24
EP0920438A2 (en)	1999-06-09
HUP0001640A3 (en)	2002-04-29
EP0992510B1 (en)	2003-03-12
NO312679B1 (no)	2002-06-17
EP1081155A2 (en)	2001-03-07
JP3157842B2 (ja)	2001-04-16
PL331853A1 (en)	1999-08-16
DK0920438T3 (da)	2001-09-10
IL128652A0 (en)	2000-01-31
DE69719816D1 (de)	2003-04-17
US5789416B1 (en)	1999-10-05
AU4080997A (en)	1998-03-19
JP2000501426A (ja)	2000-02-08

Publication	Publication Date	Title
NO20020758L (no)	1999-02-19	N<o>6</o> heterocykliske substituerte adenosinderivater
BR9711262A (pt)	1999-08-17	Derivados 6,6 substituido hetero biciclicos
IS4963A (is)	1999-01-29	Setnar 6,5-heteró-bísýklískar afleiður
FI954979A7 (fi)	1995-10-18	Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
LU91758I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
DK0920429T3 (da)	2003-05-12	Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
DE59501802D1 (de)	1998-05-14	Substituierte 1H-3-Aryl-pyrrolidin-2,4-dion-Derivate
FI914163L (fi)	1992-03-26	Heterocykliska derivat.
NL300203I1 (nl)	2005-10-03	Antiviraal werkzame heterocyclische azahexaan-derivaten.
DK1000048T3 (da)	2003-03-03	Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69718771D1 (de)	2003-03-06	Substituierte 1,2,3,4-tetrahydronaphthalinderivate
PT843679E (pt)	2002-04-29	Derivados da1-(piperidinil 1,2-disubstituido)-(4-imidazole fundido)-piperidina
ATE204279T1 (de)	2001-09-15	Diaza-spiro(3,5)nonan-derivate
ATE214063T1 (de)	2002-03-15	Heterocyclische substituierte pyrrolidinamid- derivate
BR9609310A (pt)	1999-07-06	Derivados de 1,3-OXA(TIA)ZINA
TR199700219A3 (tr)	1997-10-21	1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.

Legal Events

Date	Code	Title	Description
2012-03-26	MM1K	Lapsed by not paying the annual fees